Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Chartier

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
La Revue Du Praticien|August 20, 2016
[Not Available]Melanie Chartier, Camille Le Ray
Clinical and Experimental Rheumatology|May 13, 2010
Survey of the therapeutic management of rheumatoid arthritis in France: the OPALE studyAlain Saraux, Bernard Combe, Philippe Blin, et al.
Clinical Rheumatology|July 14, 2019
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countriesRieke Alten, Eugen Feist, Hanns-Martin Lorenz, et al.
RMD Open|February 14, 2018
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational studyRieke Alten, Xavier Mariette, Hanns-Martin Lorenz, et al.
RMD Open|March 1, 2017
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective studyRieke Alten, Hubert G Nüßlein, Xavier Mariette, et al.
Joint Bone Spine|January 4, 2017
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION studyXavier Mariette, Rieke Alten, Hubert G Nüßlein, et al.
Clinical Rheumatology|February 22, 2019
Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION studyRieke Alten, Xavier Mariette, Hanns-Martin Lorenz, et al.
Wiener Medizinische Wochenschrift (1946)|October 27, 2019
Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION studyPeter Peichl, Rieke Alten, Mauro Galeazzi, et al.
Clinical Rheumatology|June 14, 2023
Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatusRieke Alten, Hans-Peter Tony, Bettina Bannert, et al.
Clinical Rheumatology|April 12, 2019
Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION studyRieke Alten, Xavier Mariette, Hanns-Martin Lorenz, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
La Revue Du Praticien|August 20, 2016
[Not Available]Melanie Chartier, Camille Le Ray
Clinical and Experimental Rheumatology|May 13, 2010
Survey of the therapeutic management of rheumatoid arthritis in France: the OPALE studyAlain Saraux, Bernard Combe, Philippe Blin, et al.
Clinical Rheumatology|July 14, 2019
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countriesRieke Alten, Eugen Feist, Hanns-Martin Lorenz, et al.
RMD Open|February 14, 2018
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational studyRieke Alten, Xavier Mariette, Hanns-Martin Lorenz, et al.
RMD Open|March 1, 2017
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective studyRieke Alten, Hubert G Nüßlein, Xavier Mariette, et al.
Joint Bone Spine|January 4, 2017
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION studyXavier Mariette, Rieke Alten, Hubert G Nüßlein, et al.
Clinical Rheumatology|February 22, 2019
Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION studyRieke Alten, Xavier Mariette, Hanns-Martin Lorenz, et al.
Wiener Medizinische Wochenschrift (1946)|October 27, 2019
Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION studyPeter Peichl, Rieke Alten, Mauro Galeazzi, et al.
Clinical Rheumatology|June 14, 2023
Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatusRieke Alten, Hans-Peter Tony, Bettina Bannert, et al.
Clinical Rheumatology|April 12, 2019
Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION studyRieke Alten, Xavier Mariette, Hanns-Martin Lorenz, et al.
Pageof 2